More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.22B
EPS
-2.65
P/E ratio
--
Price to sales
332.37
Dividend yield
--
Beta
2.688771
Previous close
$18.70
Today's open
$18.62
Day's range
$18.10 - $18.92
52 week range
$16.11 - $30.06
show more
CEO
Clay B. Siegall
Employees
247
Headquarters
Bothell, WA
Exchange
NASDAQ Capital Market
Shares outstanding
118072943
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Immunome Analysts Cut Their Forecasts After Q3 Results
Immunome Inc (NASDAQ:IMNM) on Monday posted a wider-than-expected loss for the third quarter.
Benzinga • Nov 10, 2026

Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a business update. “We made significant progress across our oncology pipeline in recent months,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We continue to advance varegacestat toward approva.
Business Wire • Nov 9, 2026

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 206,700 shares of common stock and 103,350 restricted stock units (“RSU.
Business Wire • Nov 6, 2026

Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know
The consensus price target hints at a 74% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Nov 4, 2026

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate (ADC) for the treatment of advanced B-cell lymphomas, at the 68th American Society of Hematology (ASH) Annual Meeting. The poster will include i.
Business Wire • Nov 4, 2026

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
Zacks Investment Research • Nov 4, 2026

Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that its management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9 a.m. EST. Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company's website at www.immunome.com. The w.
Business Wire • Nov 2, 2026

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. Validation confirms that the application is complete,.
Business Wire • Oct 30, 2026

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress. The data were featured in four presentations, including a rapid oral presentation on patient-repo.
Business Wire • Oct 26, 2026

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
CNBC Television • Oct 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Immunome Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.